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One of the leading sources of false positives in early drug discovery is the formation of organic small
molecule aggregates, which inhibit enzymes nonspeciﬁcally at micromolar concentrations in aqueous solution.
The molecular basis for this widespread problem remains hazy. To investigate the mechanism of inhibition
at a molecular level, we determined changes in solvent accessibility that occur when an enzyme binds to an
aggregate using hydrogen-deuterium exchange mass spectrometry. For AmpC  -lactamase, binding to
aggregates of the small molecule rottlerin increased the deuterium exchange of all 10 reproducibly detectable
peptides, which covered 41% of the sequence of  -lactamase. This suggested a global increase in proton
accessibility upon aggregate binding, consistent with denaturation. We then investigated whether
enzyme-aggregate complexes were more susceptible to proteolysis than uninhibited enzyme. For ﬁve
aggregators, trypsin degradation of  -lactamase increased substantially when  -lactamase was inhibited by
aggregates, whereas uninhibited enzyme was generally stable to digestion. Combined, these results suggest
that the mechanism of action of aggregate-based inhibitors proceeds via partial protein unfolding when
bound to an aggregate particle.
Introduction
Many organic small molecules form submicrometer ag-
gregates at micromolar concentrations in aqueous solution.
1,2
Such molecules are found among screening hit lists, biological
reagents, and even marketed drugs.
3-11 These aggregates have
the unusual property of nonspeciﬁcally inhibiting enzyme
targets, leading to false positive “hits” in biochemical assays, a
problem that is now well-recognized, particularly in high-
throughput screening.
12-20 Still, exactly how aggregates cause
inhibition remains poorly understood.
21 Here we revisit the
speciﬁc mechanism of nonspeciﬁc inhibition by investigating
the structural changes that are induced in the enzyme upon
binding to the aggregate.
In 2003 McGovern et al. observed three mechanistic features
of small molecule aggregates that guided our investigation.
22
First, inhibition occurs via the direct binding of enzyme to
aggregate, as shown by (1) the ability to sediment protein-
aggregate complexes with centrifugation, (2) the punctate
ﬂuorescence observed by microscopy in mixtures of aggregates
with green ﬂuorescent protein (GFP
a), and (3) the direct
observation of protein-aggregate complexes by transmission
electron microscopy. Second, aggregate-based inhibition can be
rapidly reversed by the addition of a nonionic detergent such
as Triton X-100, indicating that enzyme can quickly (within
tens of seconds) regain activity from aggregate-based inhibition.
Last, several experiments appeared to be inconsistent with
denaturation as a potential mechanism of action. For example,
it seemed unlikely that enzyme could rapidly refold into its
active state upon the addition of detergent if it were completely
denatured when bound to the aggregate. It seemed equally
unlikely that GFP could retain its ﬂuorescence if it were
completely denatured while bound to an aggregate. Two other
experiments suggested that inhibition was not due to denatur-
ation: (1) additional denaturants such as guanidinium or urea
did not increase inhibition by aggregates (if anything, inhibition
was decreased) and (2) a destabilized mutant appeared to be no
more sensitive to aggregate-based inhibition than its wild type
counterpart.
As a result of McGovern’s work, we considered three possible
mechanisms of action that might explain aggregate-based
inhibition (Figure 1). Although we did not believe that there
was large scale unfolding of the enzyme, it still seemed
reasonable that there might be small-scale or local unfolding,
which has also been proposed by Ryan et al.
23 On the other
hand, aggregate binding may have the opposite effect: instead
of increasing ﬂexibility, it may rigidify it, restricting those
dynamic motions necessary for catalysis. Finally, aggregates
may physically sequester enzyme away from substrate. To
explore these potential mechanisms, we chose to use hydrogen-
deuterium exchange mass spectrometry (HDX MS), a technique
widely used to measure changes in solvent accessibility for
processes such as enzyme unfolding or protein-protein
interactions.
24-30 HDX MS relies on the different exchange rates
of the backbone amide protons with a deuterated solvent, which
are measured by the change in mass as deuterium replaces
hydrogen. To investigate changes in solvent accessibility, we
quantiﬁed deuterium exchange of AmpC  -lactamase over 8 h
in the presence or absence of an aggregating inhibitor, rottlerin.
To obtain localized information,  -lactamase was digested with
pepsin after exchange. We reproducibly observed 10 fragments
covering 41% of the entire enzyme sequence. The differences
in solvent accessibility were not localized to speciﬁc regions
(given the nonspeciﬁc nature of aggregate-based inhibition, we
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observed a general trend across all peptides. The differences in
solvent accessibility that we observed by mass spectrometry
suggested that we may also see differences in protease sensitiv-
ity, which we investigated by gel electrophoresis of tryptic
digests of our model enzyme in the presence or absence of
several known aggregating inhibitors. Combined, these experi-
ments suggest small scale enzyme unfolding as a molecular
mechanism for aggregate-based inhibition.
Results
To examine the structural changes that occur in an enzyme
when bound to a small molecule aggregate, we began by
measuring changes in solvent accessibility using HDX MS. The
experiments were conducted with AmpC  -lactamase, which
is perhaps the enzyme best characterized for aggregate-based
inhibition. Rottlerin was chosen as a model aggregator because
of the large concentration range between its critical aggregation
concentration (CAC) and when it begins to precipitate and
because of its relatively high “potency” as an aggregator (low
micromolar IC50 vs AmpC).  -Lactamase was incubated in
deuterated MOPS buffer between 10 min and 8 h, in either the
presence or absence of rottlerin. After exchange, the aggregates
were disrupted with detergent and the exchange reaction was
quenched by the addition of cold acid.  -Lactamase was
subsequently digested with immobilized pepsin to obtain
regional exchange information. These peptides were then
separated and analyzed by electrospray ionization liquid
chromatography-mass spectrometry (ESI LCMS).
Two modiﬁcations were necessary to accommodate the
presence of aggregates in the HDX MS experiment. First,
aggregate-enzyme complexes had to be exchanged in the
deuterated buffer at a lower concentration and then concentrated
before further sample preparation. Aggregates are a phase
between soluble, free small molecule and precipitant, the latter
of which does not typically inhibit enzymes, so there is an upper
limit to the concentration that we can take an aggregating
inhibitor: the concentration when it ceases to form more
aggregates and instead begins to precipitate. Typically, micro-
molar concentrations of an aggregating molecule will inhibit
nanomolar concentrations of enzyme. These HDX MS experi-
ments required micromolar concentrations of protein, and if a
corresponding concentration of inhibitor were used, we would
need an inhibitor that was soluble at millimolar concentrations.
As aggregation is a form of insolubility, there are very few
examples of molecules that have such high solubility and these
molecules are often weak aggregators and unsuitable for this
analysis.
Since we did not have an aggregator that could be used at
millimolar concentrations, we instead reduced the concentration
of the enzyme so that it would be mostly inhibited by a
preprecipitant colloidal form of the aggregator (100 µM for
rottlerin). We relied on the fact that aggregates and aggregate-
bound enzyme can be pelleted and therefore concentrated by
centrifugation. Although incubation was performed at a lower
concentration of enzyme, we could concentrate the enzyme-
aggregate complexes prior to analysis by collecting the pellet
and removing the supernatant. This has the additional beneﬁt
of guaranteeing that predominantly aggregate-bound complexes
would be analyzed, as free enzyme would not be pulled down
by centrifugation and would be many-fold lower in concentration.
The second necessary modiﬁcation was the addition of
detergent. Although we tried several detergents, none were
nearly as effective as Triton X-100. It was necessary to add
Triton mainly to release bound enzyme from the aggregates so
that the complexes were not pulled down again when centrifu-
gation was used to remove the immobilized pepsin. This resulted
in a delicate balance between using enough detergent to release
the enzyme for analysis but not so much that the detergent
signals overwhelmed the peptide signals in the mass spectra,
where Triton signals were both numerous and strong. To
increase separation between the peptide and detergent signals,
we used ESI LCMS rather than matrix-assisted laser desorption/
ionization (MALDI, which does not require peptide separ-
ation).
31,32 As a result of the presence of aggregates, the inhibited
samples generally showed much weaker signal intensities
compared to uninhibited samples. Often, the peptide signals were
so weak that they could not be analyzed. Those that were
observed were noisy, probably because of the weak intensities.
The peptides that we reproducibly observed covered 41% of
the  -lactamase sequence (Figure 2), representing several regions
of the enzyme spanning both buried and exposed regions.
Although our results are not strong enough to determine whether
speciﬁc areas experienced more exchange than others, it was
also not our goal to do so. Given that aggregates are nonspeciﬁc
inhibitors, we were searching for a global effect, a mechanism
that could explain inhibition of many enzymes and that was
not restricted to speciﬁc residues or peptide sequences. The
results suggested such a trend. Across all of the peptides that
we measured, enzyme-aggregate samples showed deuterium
incorporation greater than or equal to the deuterium incorpora-
tion of the enzyme alone (Table 1). Levels of deuteration were
very low in both samples with and without inhibitor; however,
Figure 1. Three models for the mechanism of action of promiscuous
small-molecule aggregators. (A) Binding to the aggregate promotes a
partial unfolding event. (B) Binding to the aggregate constrains protein
dynamics and restricts catalytic motions. (C) The aggregate physically
blocks the active site and sequesters enzyme away from substrate.
2068 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 7 Coan et al.the trend of higher deuterium content in the aggregate-containing
samples is consistent across all of the peptides. We suspect the
low levels of incorporation are due to increased back exchange
occurring during the protein concentration and chromatography
steps. Many peptides incorporated levels of deuterium that were
not, in themselves, entirely convincing; however, even here, each
showed more deuterium exchange in the presence of aggregates
than for the free enzyme. We never observed a peptide that
had reduced deuterium exchange in the presence of aggregates.
Two peptides that did show signiﬁcant exchange are shown in
Figure 3 (a complete list of peptides is available in the
Supporting Information). Again, we observed very low deute-
rium incorporation, but the time points repeatedly indicated a
signiﬁcant difference between samples with and without ag-
gregates. The higher deuterium incorporation of aggregate-bound
enzyme across all 10 peptides suggested that the enzyme may
be unfolded when bound to the aggregate.
If aggregates were unfolding bound enzyme, we might expect
aggregate-bound enzyme to be more susceptible to proteolytic
degradation than free, uninhibited enzyme. If an enzyme is even
slightly unfolded, it should be measurably more sensitive to
digestion by proteases (Figure 4). Given recent results showing
the very slow off rate of enzyme from the aggregate and that
the aggregate can be saturated with enzyme and so maintain a
Figure 2. Amino acid sequence and structure of AmpC  -lactamase: (A) enzyme sequence showing the peptic fragments that could be quantiﬁed
reproducibly in the mass spectrum both with and without the aggregator rottlerin; (B) two orientations of the structure of AmpC  -lactamase
indicating the location of the peptic fragments that were observed in the mass spectrum (fragments shown in purple, active site residues shown in
yellow).
39
Table 1. Summary of H/D Exchange Data for AmpC  -Lactamase in the Presence or Absence of the Aggregating Inhibitor Rottlerin
fold increase in deuteration (Dinhibited/Duninhibited) deuterium incorporation after 8 h
d
peptide
no. of amide
bonds in
peptide
a
deuterium
incorporation
after 24 h
b 10 min
c 1h
c 8h
c no inhibitor + rottlerin % solvent accessibility
e
8-18 8 1.8 1.3 2.3 2.5 0.2 ( 0.2 0.5 ( 0.2 35.7
42-56 12 6 1.9 2.7 1.8 0.8 ( 0.2 1.4 ( 0.2 44.7
105-128 20 6.6 1.6 2.6 1.8 1.5 ( 0.6 2.7 ( 0.5 31.3
109-128 16 5.4 1.5 2.5 1.6 1.4 ( 0.4 2.2 ( 0.3 36.9
132-146 11 4.2 2.6 4.2 3.4 0.3 ( 0.1 1.1 ( 0.1 34.8
243-250 6 1.8 1.2 NM
f 1.7 0.4 ( 0.2 0.7 ( 0.2 20.7
271-289 15 6.6 1.4 2.6 1.4 2.3 ( 0.5 3.1 ( 0.6 40.7
291-322 26 8 1.6 2.5 1.8 1.7 ( 0.6 3.1 ( 0.6 22.3
323-332 7 1 1.3 3.0 2.7 0.2 ( 0.0 0.5 ( 0.1 11.8
336-350 11 2.7 1.7 3.7 2.0 0.5 ( 0.2 1.0 ( 0.2 21.6
a Equal to number of amide bonds + 1, excluding prolines.
b Deuterium incorporation is calculated by subtracting the mass of the control undeuterated
centroid from the centroid of the deuterated sample. Deuterium incorporation is not corrected for back exchange.
c Indicates the amount of time the samples
were exchanged in the deuterated solvent.
d Deuterium incorporation is calculated as the (deuterated mass × charge – charge) minus (undeuterated mass ×
charge – charge) with the standard deviation of three replicate measurements.
e Average ratio of side chain surface area to random coil values per residue
calculated using Getarea.
38 Greater than 50% is considered exposed, and less that 20% is considered buried.
f Not measured.
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feasible.
33-35 We chose ﬁve known aggregators: rottlerin, Congo
Red, Eriochrome Blue Black B, nicardipine, and L-755,507.
We again used  -lactamase as our model enzyme and chose
trypsin as the protease.  -Lactamase was preincubated with or
without aggregates before the addition of trypsin to avoid
competition with trypsin for binding space on the aggregate.
Free or aggregate-bound enzyme was then incubated with
trypsin between zero min and 4 h, and the digestion was
monitored by gel electrophoresis.
For all of the aggregators, the presence of aggregates had no
effect on the band representing  -lactamase in the absence of
trypsin (Figure 5, lanes 2 and 3 or 1 and 3). In contrast, when
we added trypsin, we observed signiﬁcant digestion in the
presence of aggregates but not in the absence (Figure 5). For
example, in Figure 5A, the  -lactamase band is present in both
the aggregate-inhibited and free enzyme samples at zero minutes
(lanes 6 and 7), but as time progresses, the  -lactamase band
in the presence of rottlerin becomes weaker and weaker until it
is completely gone by 4 h (lane 15). Conversely,  -lactamase
in the absence of rottlerin appears almost as strong after 4 h
with trypsin as it did after zero min (lane 14). For Congo Red
and Eriochrome, the  -lactamase band is present in both samples
at zero min of trypsin incubation (Figure 5B,C, lanes 6 and 7),
but after only 15 min the  -lactamase band is gone in the
presence of aggregates (lane 9). Again,  -lactamase in the
absence of aggregates remains undigested by trypsin even after
4 h (lane 14). Although the effect was less pronounced, two
other aggregators, nicardipine and L-755,507, also increased
sensitivity to trypsin (Figure 5D,E). In many of these samples,
it is also possible to observe the formation of a large degradation
product of  -lactamase running below the trypsin band (Figure
5). Intriguingly, trypsin also appears to experience more self-
degradation in the presence of aggregators (Figure 5A,C, lanes
4 and 5).
Discussion
The key result to emerge from this study is the mechanism
by which association with colloidal aggregates leads to enzyme
inhibition: partial protein denaturation. Two observations support
this. The increased hydrogen-deuterium exchange of  -lacta-
mase when bound to rottlerin aggregates suggests that the
enzyme’s backbone amides are more exposed to solvent when
bound to an aggregate, indicating at least partial enzyme
denaturation (Figure 3). Consistent with this view is the
increased susceptibility of the enzyme to trypsin degradation
Figure 3. Mass envelopes and corresponding deuterium incorporation plots for two fragments from the mass spectrum of  -lactamase in the
presence (dotted line) or absence (solid line) of the aggregator rottlerin. The spectra have been expanded to show the isotopic distribution
of the ions of interest: (A) the peptide containing residues 132-146 (monoisotopic m/z ) 908.4, +2 charge state) and (B) the peptide
containing residues 291-322 (monoisotopic m/z ) 813.7, +4 charge state). For each peptide, the isotopic distributions are shown for (i) the
undeuterated sample, (ii) the sample that was deuterated for 4 h in the absence of rottlerin, and (iii) the sample that was deuterated for 4 h
in the presence of rottlerin.
2070 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 7 Coan et al.when bound to the characteristic aggregators rottlerin, Congo
Red, Eriochrome Blue Black B, nicardipine, and L-755,507
(Figure 5).
That proteins directly associate with aggregates has been
established for some time and is supported by the precipitation
of aggregate-bound protein on centrifugation, by the detection
of aggregate binding with surface plasmon resonance,
20 and by
imaging of aggregate-protein complexes by transmission
electron microscopy and ﬂuorescence microscopy.
22 What
remained perplexing was why such association should lead to
inhibition. Proteins can be attached to solid supports, as in
chromatography, without compromising their function, and so
association, per se, seemed unlikely to lead to inhibition. An
early hypothesis was that the aggregates were acting as
denaturants, but several lines of evidence seemed to tilt against
this. First, GFP retained ﬂuorescence while bound to aggregate
particles, which should not be true if GFP was substantially
denatured on aggregate association. Second, destabilized and
up-stabilized mutants of the same enzyme were inhibited to the
same extent by colloidal inhibitors, indicating that liability to
denaturation did not increase susceptibility to aggregate-based
inhibition. Third, classical denaturants such as urea or guani-
dinium failed to potentiate aggregate-based inhibition; rather,
inhibition was actually reduced in the presence of these
denaturants. Finally, disruption of the aggregates by detergent
returned enzyme activity within the dead time of the experiment,
less than 15 s, suggesting that no substantial refolding was
occurring. Whereas none of these experiments were in them-
selves conclusive, taken together they alluded to another,
unknown mechanism behind aggregate-based inhibition, and our
understanding has remained at this point for the past 5 years.
This study compels us to reevaluate our previous results. We
can reconcile the earlier and present observations by noting that
the previous study only seemed to exclude large scale protein
denaturation. More local denaturation would not be expected
to extinguish GFP ﬂuorescence
36 nor would substantial refolding
be necessary for the enzyme to regain activity upon aggregate
disruption by detergent. As to the reduced inhibition observed
in the presence of classical denaturants, we have since discov-
ered that urea and guanidinium themselves disrupt colloidal
aggregates, preventing any additive denaturant effect. Finally,
our ability to interpret the inhibitory effects of colloidal
aggregates on destabilized and up-stabilized mutant enzymes
was confounded by the CAC of the colloidal particles and their
unusually tight binding to proteins. Neither of these phenomena
were understood in 2003, but recent studies have shown that
aggregates undergo a CAC phase transition, above which their
afﬁnities for proteins are in the picomolar dissociation range or
better.
20,34,35 Given micromolar CAC values and picomolar Kd
values for the protein-aggregate interaction, one would not
expect to see differential inhibition of the mutant enzymes that
were more or less stabilized by no more than 5 kcal/mol.
Returning to our three models (Figure 1), we have ruled out
reduced dynamics and physical sequestration, as both would
have resulted in reduced solvent accessibility (less deuterium
exchange) and protection from proteolysis; rather, the reverse
is observed in both cases. Taken together, our previous studies
and current experiments suggest that on association with
colloidal, promiscuous inhibitors, proteins undergo partial
denaturation, which manifests itself as enzyme inhibition. In
such a mechanism, hydrogen-deuterium exchange would
increase, as would proteolysis, but the enzyme would not be so
denatured that it could not rapidly return to its active conforma-
tion or that GFP would not retain ﬂuorescence.
Two important caveats to these conclusions are the weak
peptide signals in the mass spectra and the low overall deuterium
incorporation. The presence of the aggregates interfered with
the HDX MS, reducing signal-to-noise and experimental
reproducibility. We suspect that we were only partially suc-
cessful at disrupting aggregate-enzyme complexes, and so lost
peptide during sample preparation. Typically this problem would
be addressed by the addition of further Triton X-100, but this
posed its own hazards for mass spectrometry because the
detergent peaks easily overwhelmed our peptide signals. De-
tergents better tolerated by mass spectrometry, such as  -oc-
taglucoside, were ineffective at disrupting the aggregates to free
the peptides for analysis. The levels of deuterium incorporation
in both the aggregate-inhibited and uninhibited samples were
Figure 4. Schematic representation of the tryptic digest experiment and interpretation. If the enzyme is unfolded on the aggregate, it should
be more susceptible to proteolysis compared to enzyme in the absence of aggregates (A). If the enzyme is in its native state when bound to
the aggregate, identical to unbound enzyme, it should be degraded at a comparable rate (B). Although some trypsin may be bound to the
aggregate, trypsin is used in excess to ensure that there is free, active trypsin in solution: (+) indicates that aggregates are present; (-)
indicates free enzyme.
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Combined with the complicating factors of low peptide signal
strength and overwhelming detergent signals, the chromato-
graphic run time had to be increased to allow separation of the
peptide and detergent peaks, thus leading to more back
exchange. We suspect that the somewhat erratic incorporation
of deuterium as a function of time is due to the low deuterium
content (which is more subject to signal-to-noise interference).
Because of the low signal-to-noise and low deuterium
incorporation, we draw no conclusions about which parts of
the enzyme are more exposed to solvent upon aggregate
binding, as would ordinarily be tempting to do with this
Figure 5. SDS-PAGE and silver stain of tryptic digests of  -lactamase in the presence (+) or absence (-) of aggregating inhibitors. The inhibitors
are (A) 100 µM rottlerin, the same inhibitor used in the HDX MS experiments, (B) 250 µM Congo Red, (C) 250 µM Eriochrome Blue Black B,
(D) 100 µM L-755,507, and (E) 250 µM nicardipine. For gels B, C, and E, lane 1 is a molecular weight ladder. For gels A and D, lane 2 is a
molecular weight ladder. Lanes 2 and 3 for gels B, C, and E or lanes 1 and 3 for gels A and D show  -lactamase without trypsin, in the absence
(-) or presence (+) of aggregator. Lanes 4 and 5 contain trypsin (no  -lactamase) in the absence and presence of aggregator, respectively. Lanes
6-15 contain tryptic digests of  -lactamase in the absence or presence of aggregator for digestion times of 0 min, 15 min, 30 min, 1 h, and 4 h
(from left to right).  -Lactamase was present at 0.5 µM in all experiments. Trypsin was used at a concentration of 0.01 mg/mL for (A), 0.025
mg/mL for (B), (C), and (D), and 0.05 mg/mL for (E). A suspected degradation product of AmpC is indicated with an arrow and labeled “dp.”
2072 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 7 Coan et al.technique. That admitted, every single peptide that we
observed had greater hydrogen-deuterium exchange in the
aggregate-bound protein compared to the free protein. This
suggests that whereas we cannot resolve the speciﬁc parts
of  -lactamase that are more denatured, the enzyme is being
partially denatured. The protease digestion experiments
support this conclusion. Inhibition by each of ﬁve different
aggregators increased susceptibility of  -lactamase to pro-
teolysis to the point where degradation was apparent within
15 min of trypsin addition, whereas digestion of uninhibited
enzyme took place over several hours (Figure 5).
Partial protein denaturation on association with colloidal
aggregates offers the ﬁrst molecular mechanism for the inhibi-
tory effects of these particles. This mechanism is attractive in
that it is general, relying on no particular feature of enzyme or
aggregate structure. All that would be required are the nonpolar,
buried residues that all enzymes possess, which might be
expected to associate with the nonpolar surfaces that the
colloidal aggregates inevitably feature. This explains the lack
of speciﬁcity of the colloidal aggregates with soluble proteins.
It also suggests the opportunity for more detailed, biophysical
studies of the sort that have long been used to characterize
protein stability and hydrophobic binding. As an aside, we note
that as denaturants, colloidal aggregates are peculiar. Their
denaturation-by-sequestration mechanism on large isolatable
particles may be unique and may lend itself to pragmatic uses.
These might include the ability to sequester proteins in a
relatively concentrated, inactive form and from a medicinal
chemistry perspective to affect the adsorption and distribution
of drugs and reagents.
4 This would be an interesting twist for
a species that until now, owing to its pervasiveness in early
drug and reagent discovery, has been only a great and recurring
problem.
At this time, several key characteristics of aggregate behavior
have come into focus. Particle formation appears to be a
common feature of organic molecules in aqueous buffer: it is
ubiquitous in early drug discovery and particularly problematic
in high-throughput screening.
1,2,9,21 As has been known for some
time, small molecule colloidal aggregates inhibit protein via
direct binding, an association that we now believe is surprisingly
tight, picomolar or better.
20,22,34 The low dissociation constant
results in little to no measurable exchange between aggregate-
bound and free protein.
33 Conversely, the aggregates themselves
are in dynamic equilibrium with their monomer small molecule
components and will rapidly dissociate when diluted below their
threshold of formation, the CAC.
35 As an aside, we note that
the CAC of an organic molecule in a particular buffer will be
relatively invariant. Whether this molecule, above its CAC, will
observably inhibit depends on other variables, including the
stoichiometric ratio of the protein it is sequestering; if unrec-
ognized, this can lead to confusion in reconciling the behavior
of a particular molecule from assay to assay. The aggregates
appear to be solid, densely packed particles, the larger of which
can bind on the order of 10 000 protein molecules. Although
we have yet to conclusively determine that protein is not
absorbed within the aggregate, adsorption to the surface has
been observed by microscopy
22 and our calculations indicate
that the particle surface has more than sufﬁcient binding capacity
to accommodate all bound protein.
35 The ﬁnal insight to this
picture is the conclusion that we have drawn here: that the
aggregate-protein interaction results in partial denaturation and
subsequent inhibition. This model appears to be true for a
number of aggregating molecules, suggesting it may be general,
but it remains unclear whether there may be different subtypes
of aggregates. Evidence of differing detergent sensitivity, size,
and binding strength suggest that there are aggregates that
behave uncharacteristically and may operate by additional
mechanisms.
20,23 Regardless, we now have a far clearer
understanding of these so often perplexing particles.
Experimental Section
Materials. AmpC  -lactamase was expressed and puriﬁed as
previously described.
37 Rottlerin, Congo Red, Eriochrome Blue
Black B, nicardipine, trypsin from porcine pancreas, and triﬂuo-
roacetic acid were purchased from Sigma-Aldrich. L-755,507 was
purchased from Tocris. Immobilized pepsin was purchased from
Pierce.
HDX MS Sample Preparation. AmpC  -lactamase (215 µM
stock in 50 mM KPi, pH 7.0) was delivered to the deuterated solvent
(50 mM MOPS buffer in D2O, pH 7.0) to a ﬁnal concentration of
16 µM for uninhibited enzyme or 0.16 µM for samples containing
the inhibitor rottlerin. The total volume of samples without rottlerin
(including the undeuterated and 100% deuterated controls) was 10
µL, whereas the total volume for each sample with rottlerin was 1
mL. The concentration of rottlerin in these samples was 100 µM
(0.5% DMSO) delivered from a 20 mM stock in DMSO. The
difference in  -lactamase concentration and total volume was to
accommodate for the limited solubility of rottlerin. Deuterium
exchange was not increased in samples containing 0.5% DMSO
(no aggregates). After incubation in the deuterated solvent for 5
min or 1, 2, 4, or 8 h, the samples containing rottlerin were
centrifuged for 5 min at 16000g to pull down and concentrate
aggregate-enzyme complexes and the top 990 µL amount was
discarded. The bottom 10 µL volume was considered the pellet
and were treated identically to the 10 µL samples without rottlerin
from this point on.
To disrupt the aggregates, 1 µL of 3% Triton X-100 in 50 mM
deuterated MOPS buffer was added to every sample and the samples
were mixed vigorously by pipetting. Immediately after, the samples
were quenched with 90 µL of ice cold 0.1% triﬂuoroacetic acid in
water, pH 2.5. The samples were mixed and transferred to 100 µL
of immobilized pepsin beads. Samples were kept on ice with
occasional mixing for 5 min, and then the pepsin beads were
sedimented by centrifugation for 1 min at 16000g at 4 °C. The
supernatant was collected and frozen with liquid nitrogen. Samples
were kept at -80 °C until analysis.
Mass Spectrometry. The mass spectrometry data were acquired
on an Applied Biosystems QSTAR Pulsar hybrid LC/MS/MS
system. The mass spectrometer was equipped with the optional
Applied Biosystems MicroIonSpray source. Chromatography was
performed using an Eldex MicroPro pump equipped with an in-
house splitter capable of producing column ﬂow rates of 0.3-1.0
µL/min at pump ﬂow rates of 50-80 µL/min. A Phenomenex Onyx
monolithic column (0.100 mm × 150 mm) was used for all
experiments. Samples were injected manually using a Valco C2-
1006 injection valve with a 1.0 µL loop. Solvent A was 0.1% formic
acid in water, and solvent B was 0.1% formic acid in acetonitrile.
Peptide Identiﬁcation. The identities of the peptides formed by
digestion with pepsin were determined by LC/MS/MS analysis
using the following conditions: column ﬂow rate was 0.4 µL/min,
and a gradient was run from 3% to 50% solvent B in 35 min. The
mass spectrometer was run using the standard information depend-
ent acquisition method. The data obtained were searched against a
database consisting only of the AmpC sequence using Protein
Prospector.
Analysis of Deuterium Incorporation. For analysis of deuter-
ated peptide samples, the same chromatography system was used.
To minimize back exchange, the column ﬂow rate was raised to
1.0 µL/min and the gradient used was from 0% to 70% solvent B
in 5 min. Total analysis time was 10-12 min per sample.
Furthermore, the injector, injection syringe, sample loop, column,
and all transfer lines were maintained in an ice bath. Data were
collected in MS mode only. All data analysis was performed with
the standard Analyst 1.1 software native to the QSTAR. The average
Aggregate-Based Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 7 2073number of deuterons incorporated for each peptide was determined
from the mass spectra. The centroid of the isotopic peak cluster
for the undeuterated control was subtracted from the centroid of
the isotopic peak cluster for each deuterated sample. The experi-
mental conditions were the same in each analysis, and only the
difference in deuterium incorporation between identical peptides
was measured, so it was not necessary to correct for back exchange.
Solvent accessible surface area was calculated using Getarea
(version 1.0 beta) available at http://curie.utmb.edu/getarea.html,
using a radius of 1.4 Å and default atomic radii and atomic solvent
parameters.
38 The average percent accessibility was calculated as
the average of the ratios of each side chain surface area to the
random coil value.
Tryptic Digests and Gel Electrophoresis. A sample of AmpC
 -lactamase (0.5 µM) was incubated in 50 mM KPi, pH 7.0, for
1 h with or without each aggregating inhibitor: 100 µM rottlerin,
250 µM Congo Red, 250 µM Eriochrome Blue Black B, 250 µM
nicardipine, or 100 µM L-755,507 (with a ﬁnal concentration of
1% DMSO in all samples, with or without inhibitor). Samples of
trypsin alone (0.01 or 0.025 mg/mL) were prepared with or without
each of the inhibitors and incubated for1ha troom temperature in
50 mM KPi, pH 7.0. Tryptic digests of  -lactamase were prepared
by ﬁrst adding 0.5 µM of the enzyme to a solution with or without
each inhibitor. After 5 min, trypsin was added to the solution and
the digests were incubated at room temperature for 0 min, 15 min,
30 min, 1 h, or 4 h. The total volume of all samples was 25 µL. To
prepare the samples for SDS-PAGE, 5 µL of loading buffer
(containing 0.25% bromophenol blue, 0.25% xylene cyanol FF, 30%
glycerol by volume, and 5 mM dithiothreitol) was added to each
sample and the samples were boiled for 2 min. Samples were mixed
by inversion, and 13 µL was added to each well. After SDS-PAGE,
protein bands were detected by silver staining.
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